This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu
Trial record 2 of 6 for:    anteris technologies

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study (DurAVR™ EFS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05712161
Recruitment Status : Active, not recruiting
First Posted : February 3, 2023
Last Update Posted : January 31, 2024
Information provided by (Responsible Party):
Anteris Technologies Ltd.

Brief Summary:
To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.

Condition or disease Intervention/treatment Phase
Aortic Stenosis Symptomatic Aortic Stenosis Severe Aortic Valve Stenosis Aortic Valve Calcification Device: DurAVRTM THV System Not Applicable

Detailed Description:

The primary objective is to assess the acute and long-term safety and feasibility of the DurAVR™ device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement as assessed by the Heart Team at the enrolling institutions.

This is a prospective, non-randomized, single-arm, multi-center Study. Subjects will be consented for follow-up to 10 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: A prospective, non-randomized, single-arm, multi-center study
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
Actual Study Start Date : August 7, 2023
Actual Primary Completion Date : December 29, 2023
Estimated Study Completion Date : December 2033

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: DurAVR™ THV System
TAVR procedure
Device: DurAVRTM THV System
The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve

Primary Outcome Measures :
  1. All-cause mortality or disabling stroke [ Time Frame: 30days ]
    Mortality would be reported as rate of death/mortality at 30 days. Disabling stroke would be reported according to VARC-3 Guidelines

  2. Technical success [ Time Frame: Immediate post procedure ]
    Freedom from mortality, successful device implant, and freedom from surgery or intervention related to the device.

Secondary Outcome Measures :
  1. All-cause mortality [ Time Frame: 30days ]
    Mortality would be reported as rate of death/mortality at 30days.

  2. Disabling stroke [ Time Frame: 30days ]
    Rate of disabling stroke according to VARC-3 Guidelines

  3. Major vascular, access-related, or cardiac structural complication [ Time Frame: 30days ]
    complications according to VARC-3 Guidelines

  4. VARC-3 Type 2-4 bleeding [ Time Frame: 30days ]
    Rates of Type 2, 3, and 4 bleeding according to VARC-3 guidelines

  5. Acute Kidney Injury stage 3 or 4 [ Time Frame: 30days ]
    AKI stage 3-4 according to VARC-3 guidelines

  6. Moderate or severe aortic regurgitation [ Time Frame: 30days ]
    aortic regurgitation according to VARC-3 guidelines

  7. New permanent pacemaker due to procedure related conduction abnormalities [ Time Frame: 30days ]
    Rate of pacemaker interventions in subjects experiencing conduction abnormalities

  8. Surgery or intervention related to the device, including aortic valve reintervention. [ Time Frame: 30days ]
    Device related interventions

Other Outcome Measures:
  1. Hospitalization (or re-hospitalization) [ Time Frame: 1 year ]
    Hospitalization (or re-hospitalization). Any admission after the index hospitalization or study enrolment to an inpatient unit or hospital ward for ≥24 h, including an emergency department stay. Hospitalizations planned for pre-existing conditions are excluded unless there is worsening of the baseline condition.

  2. Leaflet thickening and reduced motion [ Time Frame: 1year ]
    Assessing causes of valve leaflet thickening and reduced leaflet motion such as leaflet thrombosis, endocarditis, leaflet deterioration, and valve frame expansion issues.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects are eligible for entry in this study if ALL the following conditions are met:

    1. Symptomatic, severe native aortic stenosis in subjects 65 years or older
    2. Requires aortic valve replacement and is indicated for TAVR as determined by the Heart Team (composed of an experienced interventional cardiologist and an experienced cardiac surgeon)
    3. Eligible for transfemoral delivery of the DurAVR™ THV
    4. Anatomy appropriate to accommodate safe placement of DurAVR™ THV (Preprocedural measurements by TTE and CT required: aortic annulus diameter 21-23 mm by CT)
    5. Understands the study requirements and the treatment procedures and provides written informed consent
    6. Subject agrees to complete all required scheduled follow-up visits.

Exclusion Criteria:

  • Subjects are eligible for entry in this study if NONE of the following conditions are met:


  1. Anatomy precluding safe placement of DurAVR™ THV
  2. Pre-existing prosthetic heart valve in any position
  3. Unicuspid or bicuspid aortic valve
  4. Severe aortic regurgitation
  5. Severe mitral or severe tricuspid regurgitation requiring intervention.
  6. Moderate to severe mitral stenosis.
  7. Hypertrophic obstructive cardiomyopathy
  8. Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment.
  9. Severe basal septal hypertrophy with outflow gradient


  10. Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment.
  11. Determined inoperable/ineligible for surgery by the Heart Team
  12. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure
  13. Blood dyscrasias as defined: leukopenia (WBC < 1000 mm3), thrombocytopenia (platelet count < 50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states
  14. Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization
  15. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support
  16. Need for emergency surgery for any reason
  17. Ventricular dysfunction with left ventricular ejection fraction (LVEF) < 30% as measured by resting echocardiogram
  18. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
  19. Symptomatic carotid or vertebral artery disease
  20. End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min.
  21. GI bleeding within the past 3 months
  22. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, nitinol (titanium or nickel), ticlopidine and clopidogrel, contrast media
  23. Ongoing sepsis, including active endocarditis (Duke Criteria) [49]
  24. Subject refuses a blood transfusion
  25. Life expectancy < 12 months due to associated non-cardiac co-morbid conditions
  26. Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent
  27. Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
  28. Currently participating in an investigational drug or another investigational device trial
  29. Subject is contraindicated for MDCT or MRI Scans.
  30. Subject belongs to a vulnerable population (Vulnerable subject populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05712161

Layout table for location information
United States, Arizona
Tucson Medical Center
Tucson, Arizona, United States, 85712
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
Columbia University Medical Center/NYPH
New York, New York, United States, 10032
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Anteris Technologies Ltd.
Layout table for investigator information
Study Chair: Michael Reardon, MD Methodist DeBakey Hospital
Layout table for additonal information
Responsible Party: Anteris Technologies Ltd. Identifier: NCT05712161    
Other Study ID Numbers: SP0028
First Posted: February 3, 2023    Key Record Dates
Last Update Posted: January 31, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Anteris Technologies Ltd.:
Transcatheter Valve
Transcatheter Aortic Valve Implantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Constriction, Pathologic
Pathological Conditions, Anatomical
Aortic Valve Disease
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction